Key Milestone Reached in 2025

$28M Series A syndicate in formation with 5 Horizons Ventures to fund LPOXY’s SIDIPREV™ pivotal clinical trial on prevention of C. difficile infections.

Where we Started in 2020

Our patented flagship product, LP-102, is the first orally-administered metered-dose intestinal oxygen delivery therapeutic designed to prevent C. difficile colitis infections in at-risk patients undergoing antibiotic therapy.

Since inception, LPOXY Therapeutics has expanded the potential applications of LP-102 to include treating inflammatory bowel diseases – Ulcerative Colitis and Crohn’s Disease.

Poised to enter pivotal clinical trials, SIDIPREV™ represents a significant advancement in gastrointestinal healthcare, with development rigorously guided by preliminary regulatory discussions with the FDA.

View Pipeline Progress

Our Progress

Securing the necessary capital to initiate our pivotal clinical trials of SIDIPREV™, we are positioned and committed to advancing medical science for improved patient outcomes.

LPOXY Therapeutics, Inc. is a privately held biopharmaceutical corporation developing a patented portfolio of innovative treatments for patients at risk of antibiotic-induced superinfections.

Strategic Partnerships

To support our growth, LPOXY Therapeutics welcomes strategic partnerships and investment opportunities, and we invite you to join us.

For more information on investment opportunities or to stay updated on our progress, please contact us or follow us on LinkedIn.

Together, we can redefine the future of gastrointestinal treatment.

Investor Information

Latest News

Featured
LPOXY Marks C. diff Awareness Month with First-in-Class Oral Preventive Preparing for Pivotal Trial
LPOXY Marks C. diff Awareness Month with First-in-Class Oral Preventive Preparing for Pivotal Trial

C. difficile causes ten-fold more infections and excess healthcare costs than all other CDC Urgent Threat Pathogens combined. LPOXY’s upcoming STOP-Cdiff clinical trial will evaluate SIDIPREV™ in hospitalized elderly adults receiving broad-spectrum antibiotics, the highest-risk group for C. difficile infection. 

Read More →
What makes LPOXY’s approach to C. difficile prevention different
What makes LPOXY’s approach to C. difficile prevention different

A non-antibiotic approach, which means no tug-of-war with resistance and none of the stewardship headaches that bog down traditional drug rollouts. Article on LinkedIn by Jesse Landry

Read More →
LPOXY Initiates $28M Series A Financing with 5 Horizons Ventures to Fund STOP-Cdiff Pivotal Trial
LPOXY Initiates $28M Series A Financing with 5 Horizons Ventures to Fund STOP-Cdiff Pivotal Trial

Proceeds will fund the SIDIPREV™ Trial On Prevention of C.difficile Infections, positioned to become the first prevention against C.difficile, a deadly infection that claims 80 U.S. lives daily and lacks any approved preventive therapy.

Read More →